Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Recall Authority, 52397-52399 [05-17499]
Download as PDF
Federal Register / Vol. 70, No. 170 / Friday, September 2, 2005 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel: Understanding Social
Disparities in Chronic Disease Health
Outcomes, Program Announcement
Number DP–05–132; Correction
Correction: Notice of program
announcement number DP–05–132 was
published in the Federal Register on
August 12, 2005, Volume 70, Number
155, pages 47214–47215. The meeting
has been cancelled.
Time and Date: 3 p.m.–5 p.m.,
September 1, 2005 (Closed).
Meeting Location: Teleconference.
For Further Information Contact:
Gwen Cattledge, PhD, Scientific Review
Administrator, National Center for
Chronic Disease Prevention and Health
Promotion, 4770 Buford Highway, MS–
K92, Atlanta, GA 30341, Telephone
(770) 488–4655.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Diane Allen,
Director, Acting Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 05–17592 Filed 8–31–05; 11:41 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10041]
Emergency Clearance: Public
Information Collection Requirements
Submitted to the Office of Management
and Budget (OMB)
Centers for Medicare &
Medicaid Services.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
services (CMS), Department of Health
and Human Services, is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
AGENCY:
VerDate Aug<18>2005
18:00 Sep 01, 2005
Jkt 205001
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
We are, however, requesting an
emergency review of the information
collection referenced below. In
compliance with the requirement of
section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995, we have
submitted to the Office of Management
and Budget (OMB) the following
requirements for emergency review. We
are requesting an emergency review
because the collection of this
information is needed before the
expiration of the normal time limits
under OMB’s regulations at 5 CFR part
1320. This is necessary to ensure
compliance with an initiative of the
Administration.
The mandate for the collection of
information for the Long-Term Care
Awareness Project originates with a
presidential initiative in the FY 2000
budget for CMS. The overall goal of this
initiative is to help Americans and their
families with long-term health needs
through a ‘‘national campaign to
educate Medicare beneficiaries about
coverage available under the new
program and how to evaluate long-term
care options.’’ Current and future
beneficiaries now have the opportunity
to receive information from a wide
variety of printed material, telephone
information, and other electronic
resources. This collection of information
is necessary to design and test evidencebased communication strategies for a
national campaign to address the longterm health care planning needs of all
Americans.
CMS is requesting OMB review and
approval of this collection by October 3,
2005, with a 180-day approval period.
Written comments and
recommendations will be accepted from
the public if received by the individuals
designated below by October 1, 2005.
Type of Information Collection
Request: Reinstatement, with change, of
a previously approved collection for
which approval has expired; Title of
Information Collection: Long-Term Care
Awareness Campaign Demonstration
Project; Use: Data will be collected to
pilot test a national campaign to educate
current and future Medicare
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
52397
beneficiaries and their families about
long-term care needs. Project findings
will be used to design and implement a
nationwide campaign. Respondents will
be from ages 50–70; Form Number:
CMS–10041 (OMB#: 0938–0847);
Frequency: One-time; Affected Public:
Individuals or Households; Number of
Respondents: 4,500; Total Annual
Responses: 4,500; Total Annual Hours:
1,350.
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web site
address at https://www.cms.hhs.gov/
regulations/pra or E-mail your request,
including your address, phone number,
OMB number, and CMS document
identifier, to Paperwork@cms.hhs.gov,
or call the Reports Clearance Office on
(410) 786–1326.
Interested persons are invited to send
comments regarding the burden or any
other aspect of these collections of
information requirements. However, as
noted above, comments on these
information collection and
recordkeeping requirements must be
received by the designees referenced
below by October 1, 2005:
Centers for Medicare & Medicaid
Services, Office of Strategic
Operations and Regulatory Affairs,
Room C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–
1850, Attn: Melissa Musotto, CMS–
10041, and,
OMB Human Resources and Housing
Branch, Attention: Christopher
Martin, New Executive Office
Building, Room 10235, Washington,
DC 20503.
Dated: August 25, 2005.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. 05–17524 Filed 9–1–05; 8:45 am]
BILLING CODE 4120–03–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0335]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Medical Device
Recall Authority
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
E:\FR\FM\02SEN1.SGM
02SEN1
52398
Federal Register / Vol. 70, No. 170 / Friday, September 2, 2005 / Notices
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
medical device recall authority.
DATES: Submit written or electronic
comments on the collection of
information by November 1, 2005.
ADDRESSES: Submit electronic
comments on the collection of
information to: https://www.fda.gov/
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Peggy Robbins, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1223.
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
SUPPLEMENTARY INFORMATION:
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Medical Device Recall Authority—21
CFR Part 810 (OMB Number 0910–
0432)—Extension
This collection implements medical
device recall authority provisions under
section 518(e) of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
360h) and part 810 (21 CFR part 810).
Section 518(e) of the act gives FDA the
authority to issue an order requiring the
appropriate person, including
manufacturers, importers, distributors,
and retailers of a device, to immediately
cease distribution of such device, to
immediately notify health professionals
and device-user facilities of the order,
and to instruct such professionals and
facilities to cease use of such device, if
FDA finds that there is reasonable
probability that the device intended for
human use would cause serious adverse
health consequences or death.
Section 518(e) of the act sets out a
three-step procedure for issuance of a
mandatory device recall order. First, if
there is a reasonable probability that a
device intended for human use would
cause serious, adverse health
consequences or death, FDA may issue
a cease distribution and notification
order requiring the appropriate person
to immediately do the following: (1)
Cease distribution of the device, (2)
notify health professionals and device
user facilities of the order, and (3)
instruct those professionals and
facilities to cease use of the device.
Second, FDA will provide the person
named in the cease distribution and
notification order with the opportunity
for an informal hearing on whether the
order should be modified, vacated, or
amended to require a mandatory recall
of the device. Third, after providing the
opportunity for an informal hearing,
FDA may issue a mandatory recall order
if the agency determines that such an
order is necessary.
The information collected under the
recall authority will be used by FDA to
ensure that all devices entering the
market are safe and effective, to
accurately and immediately detect
serious problems with medical devices,
and to remove dangerous and defective
devices from the market.
The respondents to this proposed
collection of information are
manufacturers, importers, distributors,
and retailers of medical devices.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR Section
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
810.10(d)
2
1
2
8
16
810.11(a)
1
1
1
8
8
810.12(a) and (b)
1
1
1
8
8
810.14
2
1
2
16
32
810.15(a) through (d)
2
1
2
16
32
10
1
10
1
10
810.16
2
12
24
40
960
810.17
2
1
2
8
16
810.15(e)
VerDate Aug<18>2005
18:00 Sep 01, 2005
Jkt 205001
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
E:\FR\FM\02SEN1.SGM
02SEN1
Federal Register / Vol. 70, No. 170 / Friday, September 2, 2005 / Notices
52399
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1—Continued
No. of
Respondents
21 CFR Section
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total
1There
Total Hours
1,082
are no capital costs or operating and maintenance costs associated with this collection of information.
The following burden estimates are
based on FDA’s experience with
voluntary recalls under 21 CFR part 7.
FDA expects no more than two
mandatory recalls per year, as most
recalls are done voluntarily.
Section 810.10(d)—FDA estimates
that it will take approximately 8 hours
for the person named in a cease
distribution and notification order to
gather and submit the information
required by this section. The total
estimated annual burden is 16 hours.
Section 810.11(a)—Based on
experience in similar situations, FDA
expects that there will be only one
request for a regulatory hearing per year
and that it will take approximately 8
hours to prepare this request.
Section 810.12(a) and (b)—Based on
experience in similar situations, FDA
expects that there will be only one
written request for a review of a cease
distribution and notification order per
year and that it will take approximately
8 hours to prepare this request.
Section 810.14—Based upon its
experience with voluntary recalls, FDA
estimates that it will take approximately
16 hours to develop a strategy for
complying with the order.
Section 810.15(a) through (d)—Based
upon its experience with voluntary
recalls, FDA estimates that it will take
approximately 16 hours to notify each
health professional, user facility, or
individual of the order.
Section 810.15(e)—Based upon its
experience with voluntary recalls, FDA
estimates that there will be
approximately 5 consignees per recall
(10 per year) who will be required to
notify their consignees of the order.
FDA estimates that it will take them
about 1 hour to do so.
Section 810.16—FDA estimates that it
would take no more than 40 hours to
assemble and prepare a written status
report required by a recall. The status
reports are prepared by manufacturers 6
to 12 times each year. Therefore, each
manufacturer would spend no more
than 480 hours each year preparing
status reports. If there were two FDA
invoked recalls each year, the total
burden hours estimated would be 960
hours each year.
Section 810.17—Based on experience
with similar procedures, FDA estimates
that it would take 8 hours to draft a
VerDate Aug<18>2005
18:00 Sep 01, 2005
Jkt 205001
written request for termination of a
cease distribution and notification or
mandatory recall order.
Dated: August 26, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–17499 Filed 9–1–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Blood Products Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Blood Products
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on September 29, 2005, from 8 a.m.
to 5 p.m.
Location: Food and Drug
Administration, conference room 1066,
5630 Fishers Lane, Rockville, MD.
Contact Person: Donald W. Jehn or
Pearline K. Muckelvene, Center for
Biologics Evaluation and Research
(HFM–71), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852, 301–827–0314, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area), code
3014519516. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: On September 29, 2005, the
committee will discuss new drug
application (NDA) 21–882 proposed
trade name EXJADE (deferasirox)
Tablets for Oral Suspension, Novartis
Pharmaceutical Corp., proposed for the
indication of the treatment of chronic
iron overload due to blood transfusions
(transfusional hemosiderosis).
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Following this discussion, the
committee will hear an overview of the
research programs in the Laboratory of
Hemostasis and the Laboratory of
Plasma Derivatives, Division of
Hematology, Office of Blood Research
and Review, Center for Biologics
Evaluation and Research (CBER), and in
closed session will discuss the report
from the laboratory site visit of February
25, 2005.
Procedure: On September 29, 2005,
from 8 a.m. to 4:15 p.m., the meeting is
open to the public. Interested persons
may present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person by September 22, 2005. Oral
presentations from the public will be
scheduled between approximately 11:15
a.m. and 12:15 p.m. Time allotted for
each presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person before September 22, 2005, and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation.
Closed Committee Deliberations: On
September 29, 2005, from
approximately 4:15 p.m. to 5 p.m., the
meeting will be closed to permit
discussion where disclosure would
constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C.
552b(c)(6)). The committee will discuss
a review of internal research programs
in the Division of Hematology, Office of
Blood Research and Review, Center for
Biologics Evaluation and Research.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Donald Jehn
or Pearline K. Muckelvene at least 7
days in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
E:\FR\FM\02SEN1.SGM
02SEN1
Agencies
[Federal Register Volume 70, Number 170 (Friday, September 2, 2005)]
[Notices]
[Pages 52397-52399]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-17499]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N-0335]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Medical Device Recall Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
[[Page 52398]]
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on medical device recall
authority.
DATES: Submit written or electronic comments on the collection of
information by November 1, 2005.
ADDRESSES: Submit electronic comments on the collection of information
to: https://www.fda.gov/dockets/ecomments. Submit written comments on
the collection of information to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Peggy Robbins, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-1223.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Medical Device Recall Authority--21 CFR Part 810 (OMB Number 0910-
0432)--Extension
This collection implements medical device recall authority
provisions under section 518(e) of the Federal Food, Drug, and Cosmetic
Act (the act) (21 U.S.C. 360h) and part 810 (21 CFR part 810). Section
518(e) of the act gives FDA the authority to issue an order requiring
the appropriate person, including manufacturers, importers,
distributors, and retailers of a device, to immediately cease
distribution of such device, to immediately notify health professionals
and device-user facilities of the order, and to instruct such
professionals and facilities to cease use of such device, if FDA finds
that there is reasonable probability that the device intended for human
use would cause serious adverse health consequences or death.
Section 518(e) of the act sets out a three-step procedure for
issuance of a mandatory device recall order. First, if there is a
reasonable probability that a device intended for human use would cause
serious, adverse health consequences or death, FDA may issue a cease
distribution and notification order requiring the appropriate person to
immediately do the following: (1) Cease distribution of the device, (2)
notify health professionals and device user facilities of the order,
and (3) instruct those professionals and facilities to cease use of the
device. Second, FDA will provide the person named in the cease
distribution and notification order with the opportunity for an
informal hearing on whether the order should be modified, vacated, or
amended to require a mandatory recall of the device. Third, after
providing the opportunity for an informal hearing, FDA may issue a
mandatory recall order if the agency determines that such an order is
necessary.
The information collected under the recall authority will be used
by FDA to ensure that all devices entering the market are safe and
effective, to accurately and immediately detect serious problems with
medical devices, and to remove dangerous and defective devices from the
market.
The respondents to this proposed collection of information are
manufacturers, importers, distributors, and retailers of medical
devices.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
810.10(d) 2 1 2 8 16
----------------------------------------------------------------------------------------------------------------
810.11(a) 1 1 1 8 8
----------------------------------------------------------------------------------------------------------------
810.12(a) and (b) 1 1 1 8 8
----------------------------------------------------------------------------------------------------------------
810.14 2 1 2 16 32
----------------------------------------------------------------------------------------------------------------
810.15(a) through 2 1 2 16 32
(d)
----------------------------------------------------------------------------------------------------------------
810.15(e) 10 1 10 1 10
----------------------------------------------------------------------------------------------------------------
810.16 2 12 24 40 960
----------------------------------------------------------------------------------------------------------------
810.17 2 1 2 8 16
----------------------------------------------------------------------------------------------------------------
[[Page 52399]]
Total 1,082
----------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
The following burden estimates are based on FDA's experience with
voluntary recalls under 21 CFR part 7. FDA expects no more than two
mandatory recalls per year, as most recalls are done voluntarily.
Section 810.10(d)--FDA estimates that it will take approximately 8
hours for the person named in a cease distribution and notification
order to gather and submit the information required by this section.
The total estimated annual burden is 16 hours.
Section 810.11(a)--Based on experience in similar situations, FDA
expects that there will be only one request for a regulatory hearing
per year and that it will take approximately 8 hours to prepare this
request.
Section 810.12(a) and (b)--Based on experience in similar
situations, FDA expects that there will be only one written request for
a review of a cease distribution and notification order per year and
that it will take approximately 8 hours to prepare this request.
Section 810.14--Based upon its experience with voluntary recalls,
FDA estimates that it will take approximately 16 hours to develop a
strategy for complying with the order.
Section 810.15(a) through (d)--Based upon its experience with
voluntary recalls, FDA estimates that it will take approximately 16
hours to notify each health professional, user facility, or individual
of the order.
Section 810.15(e)--Based upon its experience with voluntary
recalls, FDA estimates that there will be approximately 5 consignees
per recall (10 per year) who will be required to notify their
consignees of the order. FDA estimates that it will take them about 1
hour to do so.
Section 810.16--FDA estimates that it would take no more than 40
hours to assemble and prepare a written status report required by a
recall. The status reports are prepared by manufacturers 6 to 12 times
each year. Therefore, each manufacturer would spend no more than 480
hours each year preparing status reports. If there were two FDA invoked
recalls each year, the total burden hours estimated would be 960 hours
each year.
Section 810.17--Based on experience with similar procedures, FDA
estimates that it would take 8 hours to draft a written request for
termination of a cease distribution and notification or mandatory
recall order.
Dated: August 26, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-17499 Filed 9-1-05; 8:45 am]
BILLING CODE 4160-01-S